View Older Stories View More Recent Stories
-
Pre-Open Stock Movers 11/05: (AWAY) (SD) (FB) Higher; (XENT) (LCI) (BLUE) Lower (more...)
-
Roth Capital Downgrades Energy Focus (EFOI) to Neutral
-
Roth Capital Downgrades Sapiens International Corp. NV (SPNS) to Neutral
-
Roth Capital Upgrades Cogentix Medical (CGNT) to Buy
-
Gerhard Erdelji Joins HomeStreet to Lead Investor Relations
-
Roth Capital Raises Price Target on MaxLinear (MXL) Following 3Q Results
-
Same-Store Sales Remain Strong; Roth Capital Remains Neutral on Denny's Corp (DENN)
-
ROTH Capital Partners to Host Technology Corporate Access Day in New York City, NY on November 18th, 2015
-
Top Image Systems to Participate in the ROTH Technology Corporate Access Day in New York
-
Better Than Anticipated Cash Costs Drive EPS Beat for Coeur Mining (CDE); Roth Capital Reiterates Buy
-
Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy
-
MeetMe (MEET) PT Bumped to $4.25 at Roth Capital Post Q3
-
Roth Capital Downgrades Enphase Energy (ENPH) to Neutral
-
Roth Affirms Rexahn Pharma (RNN) at 'Buy'; Broad POC Program Initiation, Archexin Data in mRCC on Tap
-
VBL Therapeutics (VBLT) Prices $15M Offering of Ordinary Shares and Warrants
-
Vascular Biogenics Ltd. Announces Pricing of $15 Million Underwritten Offering of Ordinary Shares and Warrants
-
Vascular Biogenics Ltd. Announces Pricing of $15 Million Underwritten Offering of Ordinary Shares and Warrants
-
Roth Capital Cuts Price Target on Constant Contact (CTCT) Following Announced Acquisition by Endurance International Group (EIGI)
-
Notable 52-Week Highs and Lows 11/2:(MGM) (GT) (NEO) High; (EIGI) (TKAI) (ENPH) Low
-
Roth Capital Expects In-Line Results From SolarEdge Technologies (SEDG) 1Q16
-
Roth Capital Cuts Price Target on Enphase Energy (ENPH) Ahead of 3Q Earnings Report
-
Escalade (ESCA) Reports 3Q EPS Miss; Roth Capital Reiterates Buy
-
Exact Sciences (EXAS) Releases Light 4Q Guidance; Roth Capital Cuts Price Target to $12
-
SolarCity's (SCTY) Kitchen Sink Quarter – Roth Capital
-
Roth Capital Upgrades GP Strategies (GPX) to Buy
-
OCTANe Set to Host 10th Annual Medical Device & Investor Forum
-
Notable Analyst Rating Changes 10/29: (LNCE) (MPEL) (PEGI) Upgraded; (RL) (DG) (ROK) Downgraded
-
Roth Capital Reiterates Buy on Ellie Mae (ELLI) Following 3Q Results
-
Roth Capital Assumes Sucampo Pharmaceuticals (SCMP) at Buy
-
Notable Analyst Rating Changes 10/28: (TWTR) (AAPL) (MAS) Upgraded; (FIVE) (MRVL) (SBLK) Downgraded
-
Roth Capital Raises Price Target to $237 on Ultimate Software Group (ULTI) Following 3Q
-
Pre-Open Stock Movers 10/28: (CMI) (HOT) (CAB) (AIG) (AAPL) Higher; (MCUR) (AKAM) (ICPT) Lower (more...)
-
Roth Capital Expects Foreign Currency Exchange Rates to Negatively Hit SodaStream's (SODA) 3Q Results
-
Roth Capital Starts Yelp (YELP) at Sell
-
Roth Capital Starts MeetMe (MEET) at Buy
-
China Yida Holding (CNYD) Forms Special Committee to Evaluate Takeover Offer
-
Roth Capital Maintains Cytokinetics (CYTJK) at 'Buy' Amid Encouraging COSMIC-HF Data
-
Adesto Technologies (IOTS) IPO Opens Higher
-
Adesto Technologies (IOTS) Prices 5M Common Stock IPO at $5/Share
-
Harris & Harris Group Portfolio Company Adesto Raises $25 Million in Initial Public Offering
-
Adesto Technologies Corporation Prices Initial Public Offering
-
Adesto Technologies Corporation Prices Initial Public Offering
-
SolarCity (SCTY) to Report 3Q Earnings on 10/29; Roth Capital Cuts Price Target to $70
-
Spark Therapeutics to Participate in Four Conferences in October and November
-
Ligand Pharma (LGND) Announces FDA CRL for Evomela's NDA; Roth Capital Reiterates Buy
-
NovaBay Pharma (NBY) Prices 12.3M Common Stock, Warrants Offering
-
NovaBay Announces Pricing of Public Offering of Common Stock and Warrants
-
Roth Capital Trims PT on Ligand (LGND) to $138; Will Remove Evomela from Revenue Projections (SPPI)
-
NovaBay Pharma (NBY) Announces Common Stock, Warrants Offering
-
NovaBay Announces Proposed Public Offering of Common Stock and Warrants

